Thus, combining HO-1 inhibitors with chemotherapy provides a promising novel therapeutic approach that addresses the challenges of acquired resistance and metastasis in PC, ultimately improving chemotherapy outcomes for PC patients. This evidence concerns the gene HMOX1 and pachyonychia congenita.